

Area Drugs and Therapeutics Committee Meeting Agenda

Wednesday 19th November 2025 10-12.30pm

Microsoft Teams Meeting

	Present	
	Veronica Rainey (Chair) Victoria Gemmell (Prof Sec) Gail Richardson Kavan Stafford Rachael Kelly Chris Miller Kirsty Macfarlane Stephanie Dundas Tyra Smyth Quorate (6 members) – Y	David Semple Eimear Gordon Colin Angus Invited Attendees: Zhou Min Chong Barry Melia James Chappell Megan Robertson
1.	Apologies for Absence	
	Sharon Murray, Craig Thurtell, Alistair Brown, Penny Brankin, Christine Carswell, Graeme Bryson	
2.	Declaration of Interest	
	Nil	
3.	Ratification of minutes of October 2025 meeting	
	These were accepted as a true reflection of the meeting and can be published	
4.	Matters arising not covered elsewhere on the agenda	
	<p>a. Produodopa Clinical Protocol – Eimear Gordon EG shared a proposed patient pathway. This was approved pending some small changes.</p> <p>b. R-hGH Guideline – Ian Hunter Update awaited.</p> <p>c. Peripheral Non-Adrenaline – Nicholas Holt Update awaited. The committee agreed this is really helpful document. Appreciation that there is a need for speed, so happy to received an amended version with the view to share with the committee for email approval.</p> <p>d. Gestational Diabetes Mellitus (GDM) – James McClaren Approved pending small amendments.</p> <p>e. Abdominal Wound Catheter Local Anaesthetic Top up Protocol – Colum Slorach discussed as Colum S attended. Feedback not given on prev version. This was approved pending small amendments.</p> <p>f. Lipid Clinic for High Risk Stroke Patients – Clayton Micallef Approved pending a small amendment.</p> <p>g. Mavacamten – Robin Weir Update awaited</p>	

Area Drugs and Therapeutics Committee Meeting Agenda

Wednesday 19th November 2025 10-12.30pm

Microsoft Teams Meeting

	<p>h. Preoperative Management of GLP-1 Agonists – Emma Murphy The committee felt inconsistencies remained regarding GLP-1 table, and it was suggested it would be more helpful to remove. TS to give feedback regarding scheduling. This was not approved.</p> <p>i. Ceftriaxone administration SBAR - Rebecca Ritchie This was approved.</p>	
5.	ADTC Committee Business	
	a. ADTC ToR – Final version for noting	
6.	SMC Advice - CONFIDENTIAL	RK
	<p>a. SMC Advice – November 2025 These were noted.</p> <p>b. SMC UO Pathway Report for Boards This was noted.</p>	
6.2	<p>Updates to NHS LK status on SMC advice RK outlined proposed updates in designations for SMC medicines. This was agreed. Advice for new SMC medicines which are set to or have breached the board decision deadline are as noted in the follow up document.</p> <p>6.3 Updates to Lanarkshire Bulletins These were agreed</p> <p>6.4 Outstanding SMC New Medicines Decisions Nil</p>	
7.	Lanarkshire Formulary / West of Scotland Formulary	KM
7.1	<p>NHSLK formulary changes proposals RK presented proposed formulary amendments which were approved. This included removal of discontinued products, small amendments to prescribing notes for safety needles, and addition of Vibegron.</p> <p>Solidifying Agents This form proposed the removal of solidifying agents as stoma accessories from the formulary. This was approved pending confirmation of declaration of interests from those who completed the form.</p> <p>Micronised Progesterone and Progestogens as Part of HRT This form proposed the addition of micronized progesterone and amendment to relevant prescribing notes. This was approved pending confirmation of declaration of interests from those who completed the form.</p> <p>FreeStyle Libre 3 Plus This proposed a switch in the formulary from FreeStyle Libre 3 to 3 Plus – this</p>	

Area Drugs and Therapeutics Committee Meeting Agenda

Wednesday 19th November 2025 10-12.30pm

Microsoft Teams Meeting

	was approved. This was approved pending confirmation of declaration of interests from those who completed the form.	
7.2	West of Scotland Formulary Updates KM gave an update on current progress. VG noted that draft chapters will be presented at ADTC as available.	KM
BREAK (10 Minutes)		
8.	Clinical Protocols & Guidelines	
	<p>a1. Abaloparatide - Zhuo Min Chong * Approved pending small amendments.</p> <p>a2. Osteoporosis Guideline – Zhuo Min Chong * Approved pending small amendments.</p> <p>b. Ryeqo Guidance – Mihai Gherghe SOPs included for context only not for ADTC approval There was request to specify in both protocols that the patient will not be discharged from specialist care until the 12 month DEXA has taken place and patient reviewed subsequent to the results. It was acknowledged that it would be helpful for the specialist team to work with the GP sub committee to allow any potential issues to be resolved. The use of Ryeqo for uterine fibroids and endometriosis was approved in NHSL.</p> <p>c. Stillbirth Management – Gordon Buchanan This was an update to existing guidance. Approved pending amendments</p> <p>d. Intravenous Fluid and Electrolyte Prescription in Adults - Megan McGowan This was not approved. Comments will be fed back to the author.</p> <p>e. Adult Parenteral Nutrition (PN) Guideline - Ruth Waters This was approved.</p> <p>f. Decompensated cirrhosis bundle - Sean Haughey 11:55 This was not approved.</p> <p>g. Department of Health and Social Care consultaion on prposed amendments to the Human Medicines Regulations – Barry Melia* 12:00 The amendments proposed by BM were accepted. VR and BM will liaise to provide feedback to DoH.</p> <p>h. Psoriasis Pathway - Carole Martin This was an update to an existing guideline. The committee felt that there are too many first and second line options, so there was an ask for streamlining. These should also tie in with the RF. This was not approved.</p>	

Area Drugs and Therapeutics Committee Meeting Agenda

Wednesday 19th November 2025 10-12.30pm

Microsoft Teams Meeting

	<p>i. Glucagon and high dose insulin for treatment of beta blocker / calcium channel blocker overdose - Deboarh Smith This an UL use of a medicine, and unusual to have a guideline as use should be minimal. Appears to be a copy of the Toxbase guidance, check the purpose/need for Lan specific guideline. This was not approved.</p> <p>j. Constipation Guideline – Lynsay McAulay The committee agreed there is a need for this guidance. There was a suggestion to widen access to include Prmiary Care would be helpful. This was not approved.</p> <p>k. Sepsis and Pyrexia - Gordon Buchanan Approved pending small amendments.</p> <p>l. Anti-D administration at 28-30 weeks of gestation - Gordon Buchanan Approved pending small amendments</p> <p>m. Day Case Spinal Anaesthesia Pathway University Hospital Wishaw – Colum Slorach CS presented the document. There was discussion around the need for Board-wide documents, however challenges were acknowledged in gaining engagement and consensus across all acute sites. VR will take this issue forward with site clinical leads. It was agreed that due to the numerous differences in service delivery at UHW, this site-specific document could be approved pending further efforts to ensure collaboration across the 3 sites. Approved pending small updates. Review date of 12 months was accepted, with a view to adoption Pan-Lanarkshire.</p> <p>n. Low risk neutropenic pathway This was approved pending small amendments.</p>	
9.	ULM Requests	
	<p>a. Updated ULM documents – Victoria Gemmell Approved pending KB comments.</p>	
10.	New Medicine Safety Notifications & Alerts	
	<p>a. CAS - Home https://www.gov.uk/drug-safety-update This was noted</p> <p>b. MHRA Safety Roundup – October 2025 This was noted</p> <p>c. Class 2 medicines recall</p>	

Area Drugs and Therapeutics Committee Meeting Agenda

Wednesday 19th November 2025 10-12.30pm

Microsoft Teams Meeting

	This was noted	
11.	Prescribing Management Board Update	GRB
11.1	NCMAG Horizon Scanning Report (Confidential) This was noted	
12.	Medicines for the Treatment of Cancer	KB
	a. NCMAG Quarterly Update – October 2025 This was noted	
13.	Medicines Code of Practice	
	Nil	
14.	PGD Activity Report	
	a. SOP for Public Health PGD Development - Barry Melia* BM gave a summary. This was approved b. PGD Activity Report RK highlighted specific PGDs where discussions are ongoing to progress to organisational approval. This report was accepted by the committee as reassurance of appropriate governance structures.	
15.	Antimicrobial Management Team Update	SD
	Nil	
16.	Lay member related items	
	Nil	
17.	Correspondence	
	Nil	
18.	AOCB	
	a. Scottish Medicines Consortium - Expressions of interest for Membership	
19.	Date of Next Meeting	
	Wednesday 17 th December 2025 10-12.30pm MS TEAMS	